Several studies now demonstrate that targeting both FLT3-dependant and FLT3-independant pathways is much more beneficial in FLT3/ITD AML patients, and also overcomes acquired resistance to selective FLT3 inhibitors [6–8]. Here, FLT3 is linked to acute myeloid leukemia.